ResMed Company Profile (NYSE:RMD)

About ResMed

ResMed logoResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: RMD
  • CUSIP: 76115210
Key Metrics:
  • Previous Close: $72.21
  • 50 Day Moving Average: $66.69
  • 200 Day Moving Average: $64.40
  • 52-Week Range: $55.13 - $72.38
  • Trailing P/E Ratio: 31.26
  • Foreward P/E Ratio: 23.14
  • P/E Growth: 2.49
  • Market Cap: $10.23B
  • Outstanding Shares: 141,656,000
  • Beta: 0.82
  • Net Margins: 16.48%
  • Return on Equity: 22.82%
  • Return on Assets: 12.66%
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 2.23%
  • Quick Ratio: 1.86%
Additional Links:
Companies Related to ResMed:

Analyst Ratings

Consensus Ratings for ResMed (NYSE:RMD) (?)
Ratings Breakdown: 4 Sell Ratings, 4 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 1.91)
Consensus Price Target: $60.88 (15.70% downside)

Analysts' Ratings History for ResMed (NYSE:RMD)
DateFirmActionRatingPrice TargetDetails
2/6/2017Canaccord GenuityReiterated RatingHold$59.00View Rating Details
1/24/2017J P Morgan Chase & CoUpgradeNeutral -> Overweight$72.00View Rating Details
1/24/2017Needham & Company LLCReiterated RatingSellView Rating Details
1/24/2017BMO Capital MarketsReiterated RatingHold$61.00View Rating Details
1/24/2017Barclays PLCBoost Price TargetUnderweight$55.00 -> $60.00View Rating Details
10/26/2016Jefferies Group LLCLower Price Target$56.00View Rating Details
9/29/2016Bank of America CorpUpgradeNeutral -> Buy$89.00 -> $72.00View Rating Details
8/29/2016Northland SecuritiesSet Price TargetSell$50.00View Rating Details
4/27/2016MacquarieUpgradeUnderperform -> NeutralView Rating Details
4/27/2016Citigroup Inc.UpgradeNeutral -> BuyView Rating Details
4/27/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$65.00 -> $57.00View Rating Details
1/22/2016Credit Suisse GroupUpgradeNeutral -> OutperformView Rating Details
10/6/2015Deutsche Bank AGUpgradeSell -> Hold$53.00 -> $56.00View Rating Details
9/24/2015Goldman Sachs Group, Inc. (The)UpgradeNeutral -> Conviction-BuyView Rating Details
7/31/2015Morgan StanleyUpgradeEqual Weight -> OverweightView Rating Details
(Data available from 2/21/2015 forward)


Earnings History for ResMed (NYSE:RMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/23/2017Q217$0.70$0.73$518.60 million$530.40 millionViewN/AView Earnings Details
10/25/2016Q117$0.64$0.62$475.05 million$465.45 millionViewListenView Earnings Details
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ResMed (NYSE:RMD)
Current Year EPS Consensus Estimate: $2.82 EPS
Next Year EPS Consensus Estimate: $3.12 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.70$0.73$0.72
Q2 20162$0.75$0.75$0.75
Q3 20161$0.68$0.68$0.68
Q4 20163$0.75$0.76$0.75
Q1 20173$0.57$0.64$0.61
Q2 20173$0.69$0.70$0.69
Q3 20173$0.65$0.70$0.68
Q4 20173$0.72$0.77$0.74
Q1 20182$0.65$0.67$0.66
Q2 20182$0.77$0.79$0.78
Q3 20182$0.75$0.77$0.76
Q4 20182$0.78$0.86$0.82
(Data provided by Zacks Investment Research)


Current Dividend Information for ResMed (NYSE:RMD)
Annual Dividend:$1.32
Dividend Yield:1.83%
Dividend Growth:14.50% (3 Year Average)
Payout Ratio:57.39% (Based on Trailing 12 Months of Earnings)
46.81% (Based on Current Year Consensus EPS Estimate)
42.31% (Based on Next Year Consensus EPS Estimate)

Dividend History for ResMed (NYSE:RMD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for ResMed (NYSE:RMD)
Insider Ownership Percentage: 1.97%
Institutional Ownership Percentage: 62.51%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/20/2017Christopher G RobertsDirectorSell10,000$71.91$719,100.00View SEC Filing  
2/15/2017Franz KozichDirectorBuy50,000$0.05$2,500.00
2/14/2017Warren Russell HawkinsDirectorBuy60,000$0.05$3,000.00
2/6/2017Peter C FarrellDirectorSell20,000$68.32$1,366,400.00View SEC Filing  
2/3/2017David PendarvisInsiderSell6,365$67.16$427,473.40View SEC Filing  
1/17/2017James HollingsheadInsiderSell7,084$64.44$456,492.96View SEC Filing  
1/4/2017Peter C FarrellDirectorSell20,000$62.14$1,242,800.00View SEC Filing  
1/3/2017David PendarvisInsiderSell6,365$61.95$394,311.75View SEC Filing  
12/5/2016David PendarvisInsiderSell6,365$60.00$381,900.00View SEC Filing  
12/5/2016Peter C FarrellDirectorSell20,000$59.83$1,196,600.00View SEC Filing  
11/4/2016Peter C FarrellDirectorSell20,000$57.28$1,145,600.00View SEC Filing  
11/3/2016David PendarvisInsiderSell6,033$57.79$348,647.07View SEC Filing  
10/18/2016James HollingsheadInsiderSell1,967$64.71$127,284.57View SEC Filing  
10/17/2016James HollingsheadInsiderSell5,264$64.43$339,159.52View SEC Filing  
10/17/2016Michael J FarrellCEOSell5,975$64.25$383,893.75View SEC Filing  
10/4/2016Peter C FarrellDirectorSell20,000$64.70$1,294,000.00View SEC Filing  
10/3/2016David PendarvisInsiderSell6,000$63.95$383,700.00View SEC Filing  
9/15/2016Michael J. FarrellCEOSell5,975$64.84$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000$67.18$403,080.00View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000$67.29$1,345,800.00View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000$69.93$2,517,480.00View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487$69.13$171,926.31View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102$69.25$1,599,813.50View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975$70.41$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000$70.50$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000$70.15$2,525,400.00View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390$70.32$1,715,104.80View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000$69.16$1,383,200.00View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000$68.86$413,160.00View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975$65.03$388,554.25View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753$65.02$179,000.06View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000$63.62$1,272,400.00View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000$63.62$381,720.00View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458$59.40$264,805.20View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975$59.63$356,289.25View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000$59.82$1,196,400.00View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000$59.41$356,460.00View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975$57.64$344,399.00View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000$55.90$1,118,000.00View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000$56.02$336,120.00View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975$59.34$354,556.50View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000$58.70$352,200.00View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500$58.57$263,565.00View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975$58.57$349,955.75View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000$60.00$2,160,000.00View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000$57.26$343,560.00View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946$57.06$111,038.76View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000$57.61$1,728,300.00View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000$57.88$2,083,680.00View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980$57.31$8,022,253.80View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975$58.20$347,745.00View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000$57.70$1,154,000.00View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000$57.43$344,580.00View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000$0.04$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975$53.07$317,093.25View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000$52.16$312,960.00View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000$52.22$1,044,400.00View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337$52.97$335,670.89View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500$55.95$251,775.00View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000$59.38$356,280.00View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333$59.77$378,523.41View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000$0.06$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000$0.06$165.00
11/20/2015Christopher G RobertsDirectorSell12,000$59.03$708,360.00View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975$57.03$340,754.25View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442$57.72$1,468,512.24View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333$57.60$364,780.80View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000$57.01$171,030.00View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975$55.35$330,716.25View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500$52.47$288,585.00View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333$52.13$330,139.29View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169$50.93$1,383,717.17View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455$50.67$225,734.85View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975$50.89$304,067.75View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500$51.78$284,790.00View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333$52.04$329,569.32View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000$50.82$1,829,520.00View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000$52.26$313,560.00View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860$51.83$562,873.80View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975$55.54$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975$57.59$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500$55.19$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000$55.61$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333$56.59$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975$57.87$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500$59.41$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000$59.25$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333$59.22$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500$65.10$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500$72.60$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000$70.70$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333$70.67$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000$0.09$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000$0.08$800.00
3/16/2015Anne ReiserInsiderSell4,000$69.10$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975$69.10$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000$66.75$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000$64.64$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333$64.39$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000$66.11$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500$62.35$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000$63.49$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670$62.82$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333$62.35$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000$61.97$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000$66.77$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500$57.09$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000$56.99$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000$56.99$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000$53.28$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000$52.93$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000$52.39$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557$52.00$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000$51.84$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204$51.84$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000$49.84$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000$49.11$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200$52.41$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000$52.99$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000$53.23$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000$53.23$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000$53.37$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000$49.12$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000$49.04$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000$48.95$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200$49.22$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000$50.04$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000$50.09$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200$53.20$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000$49.76$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000$49.57$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000$49.73$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700$50.54$186,998.00View SEC Filing  
5/13/2014John WarehamDirectorSell18,000$51.00$918,000.00View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000$50.00$250,000.00View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290$50.00$214,500.00View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000$49.80$1,245,000.00View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000$49.75$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000$50.01$750,150.00View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000$48.01$3,600,750.00View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000$44.95$224,750.00View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.00View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.00View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.00View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.52View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.00View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for ResMed (NYSE:RMD)
News IconSerena Williams brings the muscle to her Sports Illustrated bikinis (NYSE:RMD) - February 16 at 7:12 PM logoResMed Named Global Leader in Remote Patient Monitoring (NYSE:RMD) - February 14 at 5:53 AM
News IconTraders Secrets on Oceaneering International, Inc. (OII), ResMed Inc. (RMD) - StockNewsJournal (NYSE:RMD) - February 8 at 11:29 PM
News IconAnalyst's Indicator Review for Kilroy Realty Corporation (KRC), ResMed Inc. (RMD) - The USA Commerce (NYSE:RMD) - February 7 at 11:26 PM logoResMed Inc. (RMD) Ex-Dividend Date Scheduled for February 07, 2017 - Nasdaq (NYSE:RMD) - February 7 at 8:23 AM
News IconChief Administrative Officer of ResMed Inc (NYSE:RMD), Pendarvis David, sells 6,365 shares worth $427,473 (NYSE:RMD) - February 6 at 7:40 PM
News IconChart Indicator Check on Shares of ResMed Inc. (RMD.AX) - Market Point (NYSE:RMD) - January 31 at 1:21 AM
News IconSignal Watch: Checking the Numbers for ResMed Inc. (RMD.AX) - Market Point (NYSE:RMD) - January 30 at 8:21 PM
News IconLafleur & Godfrey LLC Has Decreased Its Holding in Resmed INC Com (RMD) by $3.58 Million (NYSE:RMD) - January 28 at 6:10 AM logoResmed Inc. (RMD) Climbed To A 5-Month High On Better Than Expected Q2 Earnings (NYSE:RMD) - January 26 at 3:41 AM logoRESMED INC Files SEC form 10-Q, Quarterly Report (NYSE:RMD) - January 26 at 3:41 AM logoResMed's Revenue Jumps, but Higher Costs Keep Profits in Check (NYSE:RMD) - January 26 at 3:41 AM logoETFs with exposure to ResMed, Inc. : January 25, 2017 (NYSE:RMD) - January 26 at 3:41 AM
News IconResmed Inc. (RMD) Is Heading Higher After Q2 Profit Surpassed Expectations (NYSE:RMD) - January 25 at 2:48 AM logoResMed upgraded by JP Morgan (NYSE:RMD) - January 25 at 2:48 AM logoMorning Movers: Lockheed Martin Tumbles, Johnson & Johnson Slips, AK Steel Soars (NYSE:RMD) - January 25 at 2:48 AM logoResMed, Inc. :RMD-US: Earnings Analysis: Q2, 2017 By the Numbers : January 24, 2017 (NYSE:RMD) - January 25 at 2:48 AM logoWhy ResMed Is in the Green Today (NYSE:RMD) - January 25 at 2:48 AM
News IconResmed Inc Receives a Hold from Canaccord Genuity (NYSE:RMD) - January 24 at 9:48 PM
News IconMedical device company to watch: Resmed Inc (NASDAQ: RMD) (NYSE:RMD) - January 24 at 9:48 PM logoResMed Reports Q2 Profit of $76.7M (RMD) (NYSE:RMD) - January 24 at 9:48 PM
News IconResMed Inc (NYSE:RMD) Stock Is Fairly Priced (NYSE:RMD) - January 24 at 9:48 PM logoBreaking Out: ResMed Stock Launches As Fiscal Q2 Sales, EPS Beat (NYSE:RMD) - January 24 at 9:48 PM logoResMed stock surges after strong quarterly results (NYSE:RMD) - January 24 at 9:48 PM logoHere's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17) (NYSE:RMD) - January 24 at 9:48 PM logoResMed: Cramer's Top Takeaways (NYSE:RMD) - January 24 at 9:48 PM
News IconStocks To Watch: Yahoo! Inc. (NASDAQ:YHOO), ResMed Inc (NYSE:RMD), Mercury Systems Inc (NASDAQ:MRCY ... - Stock Market Daily (blog) (NYSE:RMD) - January 24 at 8:07 AM logoResmed Inc. (RMD) Is Heading Higher After Q2 Profit Surpassed Expectations - RTT News (NYSE:RMD) - January 24 at 8:07 AM
News IconZack Snyder: Superman plays a big part in 'Justice League' (NYSE:RMD) - January 24 at 12:55 AM
News IconResMed Inc. (RMD) Shares Bought by Advisors Asset Management Inc (NYSE:RMD) - January 24 at 12:55 AM logoResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2017 (NYSE:RMD) - January 24 at 12:55 AM logoRESMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements and (NYSE:RMD) - January 24 at 12:55 AM
News IconEarnings in Full Force, Analysts Take Aim at ResMed Inc. (NYSE:RMD) - Wall Street Beacon (NYSE:RMD) - January 23 at 7:54 PM logoInteresting RMD Put And Call Options For March 17th - Nasdaq (NYSE:RMD) - January 23 at 7:54 PM
News IconResMed Inc. (NYSE:RMD) to Post $0.7 Earnings Per Share: Analysts - Wall Street Beacon (NYSE:RMD) - January 23 at 7:54 PM
News IconResMed Inc (ASX:RMD): What does the future look like? (NYSE:RMD) - January 23 at 9:01 AM logoQ2 2017 ResMed Inc Earnings Release - 4:00 pm ET (NYSE:RMD) - January 23 at 9:01 AM logoResMed : and BMC/3B Medical Settle Global Litigation (NYSE:RMD) - January 20 at 10:55 PM logoResMed and BMC/3B Medical Settle Global Litigation (NYSE:RMD) - January 20 at 10:55 PM logoRESMED INC Financials (NYSE:RMD) - January 18 at 8:11 PM
News IconStock of the Day: Resmed Inc (NYSE:RMD) Quarterly Sentiment ... - Baxley Report (NYSE:RMD) - January 18 at 12:56 AM
News IconWill The Needle Move For ResMed Inc. (NYSE:RMD) Shares This Earnings Season? - Wall Street Beacon (NYSE:RMD) - January 16 at 1:40 PM logoResMed's myAir™ Significantly Improves Adherence to CPAP Therapy in Patients with Sleep Apnea (NYSE:RMD) - January 12 at 8:17 PM logoRESMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation (NYSE:RMD) - January 12 at 8:17 PM logoFDA Clears World's Smallest CPAP, ResMed AirMini™ (NYSE:RMD) - January 9 at 9:03 PM logo9:04 am ResMed announces that the FDA has cleared ResMed's AirMini, the world's smallest continuous positive airway pressure (:CPAP) device (NYSE:RMD) - January 9 at 9:03 PM
News IconResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders - Yahoo Sports (NYSE:RMD) - January 9 at 8:49 AM logoCES: These Gadgets Will Literally Put You To Sleep (NYSE:RMD) - January 8 at 12:14 AM logoDr. Oz, ResMed Launch SleepScore Labs - Promising the World a Better Night's Sleep (NYSE:RMD) - January 6 at 8:55 PM logoLargest Consumer Sleep Study Just Released at CES 2017 (NYSE:RMD) - January 6 at 8:55 PM


What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Monday, January 23rd. Shareholders of record on Thursday, February 9th will be paid a dividend of $0.33 per share on Thursday, March 16th. This represents a $1.32 annualized dividend and a dividend yield of 1.83%. The ex-dividend date of this dividend is Tuesday, February 7th.

Where is ResMed's stock going? Where will ResMed's stock price be in 2017?

11 brokerages have issued 12 month price targets for ResMed's stock. Their predictions range from $50.00 to $72.00. On average, they expect ResMed's share price to reach $60.88 in the next year.

When will ResMed announce their earnings?

ResMed is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.

What are analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:

  • According to Zacks Investment Research, "ResMed reported an impressive second quarter of fiscal 2017, with both earnings and revenues ahead of the respective Zacks Consensus Estimate. The top line growth was driven primarily by a solid performance in the U.S. Share price trend over the past three months that traded significantly above the broader Medical Products Industry, also reflects this bullish show. Moreover ResMed’s product launches and new strategies to capture SDB market also boosted the earnings. On the flip side, even though the company's mask sales in the combined EMEA and APAC regions declined year-over-year, it registered a growth in U.S. Its rising operating expenses is also a matter of concern. However, challenges like rising operating costs, currency headwinds competitive bidding and reimbursement issues continue to plague the stock." (2/21/2017)

  • Needham & Company LLC analysts commented, "RMD’s revenue and EPS beat consensus in F2Q17. RMD’s gross margin was lower than expected as price declines and mix (both product and geographic) were partially offset by manufacturing efficiencies and the Brightree acquisition. However, this was offset by lower than expected SG&A and R&D expense and RMD’s operating margin beat our estimate. Despite the headline results, this wasn’t a clean quarter in our view since flow generator growth of 17% CC was helped by a few temporary factors (the AirStart liquidation and some stocking orders in China), mask growth was disappointing at 2% CC, and gross margin declined significantly on an organic basis." (1/24/2017)

  • Canaccord Genuity analysts commented, "We like the direction RMD is taking with the Brightree acquisition, toward the higher margin and faster-growing informatics/software space, which is complementary to, and could augment (long-term) the small but burgeoning, ventilator-focused COPD market and more mature, price-deflationary OSA market." (2/23/2016)

Who owns ResMed stock?

ResMed's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.56%), State Street Corp (3.18%), FMR LLC (2.78%), Matthews International Capital Management LLC (0.77%), Congress Asset Management Co. MA (0.61%) and Janus Capital Management LLC (0.51%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Donald Darkin, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins.

Who sold ResMed stock? Who is selling ResMed stock?

ResMed's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Columbia Wanger Asset Management LLC, FMR LLC, Two Sigma Investments LP, Baillie Gifford & Co., AQR Capital Management LLC, State Street Corp and Nicholas Co. Inc. WI. Company insiders that have sold ResMed stock in the last year include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Richard Sulpizio and Ronald R Taylor.

Who bought ResMed stock? Who is buying ResMed stock?

ResMed's stock was acquired by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Russell Investments Group Ltd., Janus Capital Management LLC, Asset Management One Co. Ltd., Shelton Capital Management, Motley Fool Wealth Management LLC, Tandem Investment Advisors Inc. and Marshall Wace LLP. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Ronald R Taylor and Warren Russell Hawkins.

How do I buy ResMed stock?

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ResMed stock cost?

One share of ResMed stock can currently be purchased for approximately $72.21.

ResMed (NYSE:RMD) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Earnings History Chart

Earnings by Quarter for ResMed (NYSE:RMD)

Dividend History Chart

Dividend Payments by Quarter for ResMed (NYSE:RMD)

Last Updated on 2/21/2017 by Staff